Back to top

Analyst Blog

Raptor Pharmaceuticals Corp. (RPTP - Snapshot Report) recently announced that Procysbi has been approved for marketing as an orphan medicinal product in the EU for the treatment of proven nephropathic cystinosis. Approval was expected as the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had rendered a positive opinion regarding Procysbi in Jun 2013.

The company had also received a positive opinion on Procysbi from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for orphan medicinal product exclusivity in Jul 2013 for the treatment of proven nephropathic cystinosis.

The orphan drug status will provide Procysbi 10 years of market exclusivity in the EU.

We remind investors that Procysbi was approved by the U.S. Food and Drug Administration (FDA) on Apr 30, 2013 for the treatment of nephropathic cystinosis in adults as well as children above 6 years of age. The drug was launched in Jun 2013. Moreover, Procysbi enjoys orphan drug status in the U.S.

On receiving U.S. approval for Procysbi, Raptor Pharma received the second tranche of $25 million, under its loan agreement with HealthCare Royalty Partners (HC Royalty). In Dec 2012, the companies had signed a loan agreement under which Raptor Pharma agreed to borrow $50 million for Procysbi in two tranches. The first tranche of $25 million was received in Dec 2012. The loan is expected to mature in 2019.

Meanwhile, Procysbi is being evaluated for other indications as well. Procysbi is currently in a phase II/III study for the treatment of Huntington’s disease. The company has orphan drug status in the U.S. for Procysbi for the Huntington’s disease indication. The company expects data from this study in the first quarter of 2014.

Procysbi is being studied in a phase IIb trial for the treatment of nonalcoholic fatty liver in children (NAFLD). Raptor Pharma expects to complete patient enrollment in the first half of 2014.

Raptor Pharma currently carries a Zacks Rank #3 (Hold). Currently, companies which look attractive include Gilead Sciences Inc. (GILD - Analyst Report) and Actelion Ltd. (ALIOF) with a Zacks Rank #1 (Strong Buy), and Jazz Pharmaceuticals (JAZZ - Analyst Report) with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%